|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 23 |
| 2 | XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer显示文摘DNA 修理能力(DRC ) 向基于铂的化疗与癌症房间的敏感被相关。我们假设那在 DNA 的基因多型性修理基因 XPA (干皮病 pigmentosum 组 A )和 XPG (干皮病 pigmentosum 组 G )( ERCC5 ,切除修理跨互补的组 5 ),它在 DNA 修理效率导致内部个人的差别,可以在先进非小的房间肺癌症( NSCLC )预言临床的反应到铂代理人病人。在这研究,我们发现 XPA A23G 多型性的 A G 变化显著地增加了反应到基于铂的化疗。在 XPG His46His 的多型性与减少的治疗回答被联系,但是不是统计上重要的。 | Jifeng Feng Xinchen Sun Ning Sun Shukui Qin Fan Li Hongyan Cheng Baoan Chen YuanDong Cao Jun Ma Lu Cheng Zuhong Lu Jiazhong Ji Yingfeng Zhou | 2009 | Acta Biochimica et Biophysica Sinica2009，41，5： | 8 |
| 3 | Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)显示文摘 | Lin Shen Jin Li Jianming Xu Hongming Pan Guanghai Dai Shukui Qin Liwei Wang Jinwan Wang Zhenzhou Yang Yongqian Shu Ruihua Xu Lei Chen Yunpeng Liu Shiying Yu Lilian Bu Yongzhe Piao | 2015 | Gastric Cancer2015，，1： | 7 |
| 4 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial显示文摘 | Ann-Lii Cheng Zhongzhen Guan Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Tsai-Sheng Yang Won Young Tak Hongming Pan Shiying Yu Jianming Xu Fang Fang Jessie Zou Giuseppe Lentini Dimitris Voliotis Yoon-Koo Kang | 2011 | European Journal of Cancer2011，，10： | 4 |
| 5 | Chinese expert consensus on conversion therapy for hepatocellular carcinoma(2021 edition)显示文摘Recent advances in systemic and locoregional treatments for patients with unresectable or advanced hepatocellular carcinoma(HCC)have resulted in improved response rates.This has provided an opportunity for selected patients with initially unresectable HCC to achieve adequate tumor downstaging to undergo surgical resection,a‘conversion therapy’strategy.However,conversion therapy is a new approach to the treatment of HCC and its practice and treatment protocols are still being developed.Review the evidence for conversion therapy in HCC and develop consensus statements to guide clinical practice.Evidence review:Many research centers in China have accumulated significant experience implementing HCC conversion therapy.Preliminary findings and data have shown that conversion therapy represents an important strategy to maximize the survival of selected patients with intermediate stage to advanced HCC;however,there are still many urgent clinical and scientific challenges for this therapeutic strategy and its related fields.In order to summarize and learn from past experience and review current challenges,the Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma(2021 Edition)was developed based on a review of preliminary experience and clinical data from Chinese and non-Chinese studies in this field and combined with recommendations for clinical practice.Sixteen consensus statements on the implementation of conversion therapy for HCC were developed.The statements generated in this review are based on a review of clinical evidence and real clinical experience and will help guide future progress in conversion therapy for patients with HCC. | Hui-Chuan Sun Jian Zhou Zheng Wang Xiufeng Liu Qing Xie Weidong Jia Ming Zhao Xinyu Bi Gong Li Xueli Bai Yuan Ji Li Xu Xiao-Dong Zhu Dousheng Bai Yajin Chen Yongjun Chen Chaoliu Dai Rongping Guo Wenzhi Guo Chunyi Hao Tao Huang Zhiyong Huang Deyu Li Gang Li Tao Li Xiangcheng Li Guangming Li Xiao Liang Jingfeng Liu Fubao Liu Shichun Lu Zheng Lu Weifu Lv Yilei Mao Guoliang Shao Yinghong Shi Tianqiang Song Guang Tan Yunqiang Tang Kaishan Tao Chidan Wan Guangyi Wang Lu Wang Shunxiang Wang Tianfu Wen Baocai Xing Bangde Xiang Sheng Yan Dinghua Yang Guowen Yin Tao Yin Zhenyu Yin Zhengping Yu Bixiang Zhang Jialin Zhang Shuijun Zhang Ti Zhang Yamin Zhang Yubao Zhang Aibin Zhang Haitao Zhao Ledu Zhou Wu Zhang Zhenyu Zhu Shukui Qin Feng Shen Xiujun Cai Gaojun Teng Jianqiang Cai Minshan Chen Qiang Li Lianxin Liu Weilin Wang Tingbo Liang Jiahong Dong Xiaoping Chen Xuehao Wang Shusen Zheng Jia Fan 无 | 2022 | Hepatobiliary Surgery and Nutrition2022，11，2： | 4 |
| 6 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 3 |
| 7 | First experimental constraints on WIMP couplings in the effective field theory framework from CDEX显示文摘We present weakly interacting massive particles(WIMPs) search results performed using two approaches of effective field theory from the China Dark Matter Experiment(CDEX), based on the data from both CDEX-1B and CDEX-10 stages. In the nonrelativistic effective field theory approach, both time-integrated and annual modulation analyses were used to set new limits for the coupling of WIMP-nucleon effective operators at 90% confidence level(C.L.) and improve over the current bounds in the low mχregion. In the chiral effective field theory approach, data from CDEX-10 were used to set an upper limit on WIMP-pion coupling at 90% C.L. We for the first time extended the limit to the m_(χ)<6 GeV/c^(2) region. | Yi Wang Zhi Zeng Qian Yue LiTao Yang KeJun Kang YuanJing Li Mehment Agartioglu HaiPeng An JianPing Chang JingHan Chen YunHua Chen JianPing Cheng Cheng Yi Chiang WenHan Dai Zhi Deng ChangHao Fang XinPing Geng Hui Gong QiuJu Guo XuYuan Guo HongJian He Li He ShengMing He JinWei Hu TuChen Huang HanXiong Huang HaiTao Jia LiPing Jia Xi Jiang HauBin Li JianMin Li Jin Li MingXuan Li RenMingJie Li Xia Li YuLan Li Bin Liao FongKay Lin ShinTed Lin ShuKui Liu YanDong Liu Yu Liu YuanYuan Liu ZhongZhi Liu Hao Ma YuCai Mao QiYuan Nie JinHua Ning Hui Pan NingChun Qi Jie Ren XiChao Ruan ChangSong Shang Vivek Sharma Ze She Lakhwinder Singh Monoj Kumar Singh TianXi Sun ChangJian Tang WeiYou Tang Yang Tian GuangFu Wang Li Wang Qing Wang Yu Chen Wang YunXiang Wang Zhen Wang Henry Tsz-King Wong ShiYong Wu YuCheng Wu HaoYang Xing Yin Xu Tao Xue YuLu Yan Nan Yi ChunXu Yu HaiJun Yu JianFeng Yue Ming Zeng BingTao Zhang Lei Zhang FengShou Zhang ZhenYu Zhang KangKang Zhao MingGang Zhao JiFang Zhou ZuYing Zhou JingJun Zhu | 2021 | Science China(Physics,Mechanics & Astronomy)2021，64，8： | 3 |
| 8 | First results on ^(76)Ge neutrinoless double beta decay from CDEX-1 experiment显示文摘We report the first results on ^(76)Ge neutrinoless double beta decay from stage one of the China dark-matter experiment(CDEX).A p-type point-contact high-purity germanium detector with a mass of 994 g has been installed to detect neutrinoless double beta decay events, as well as to directly detect dark matter particles. An exposure of 304 kg d has been analyzed over a wide spectral band from 500 keV to 3 MeV. The average event rate obtained was about 0.012 counts per keV per kg per day over the 2.039 MeV energy range. The half-life of ^(76)Ge neutrinoless double beta decay derived based on this result is T^(0ν)1/2>6.4×10^(22) yr(90% C.L.). An upper limit on the effective Majorana-neutrino mass of 5.0 eV has been achieved. | Li Wang Qian Yue KeJun Kang JianPing Cheng YuanJing Li TszKing Henry Wong ShinTed Lin JianPing Chang JingHan Chen QingHao Chen YunHua Chen Zhi Deng Qiang Du Hui Gong Li He QingJu He JinWei Hu HanXiong Huang TengRui Huang LiPing Jia Hao Jiang HauBin Li Hong Li JianMin Li Jin Li Jun Li Xia Li XueQian Li YuLan Li FongKay Lin ShuKui Liu Hao Ma JingLu Ma XingYu Pan Jie Ren XiChao Ruan ManBin Shen Vivek Sharma Lakhwinder Singh Manoj Kumar Singh Manoj Kumar Singh Arun Kumar Soma ChangJian Tang WeiYou Tang ChaoHsiung Tseng JiMin Wang Qing Wang ShiYong Wu YuCheng Wu HaoYang Xing Yin Xu Tao Xue LiTao Yang SongWei Yang Nan Yi ChunXu Yu HaiJun Yu WeiHe Zeng XiongHui Zeng Zhi Zeng Lan Zhang YunHua Zhang MingGang Zhao Wei Zhao JiFang Zhou ZuYing Zhou JingJun Zhu WeiBin Zhu ZhongHua Zhu | 2017 | Science China(Physics,Mechanics & Astronomy)2017，60，7： | 3 |
| 9 | The roles of ADIPOQ genetic variations in cancer risk: evidence from published studies显示文摘 | Yeqiong Xu Bangshun He Yuqin Pan Ling Gu Zhenlin Nie Liping Chen Rui Li Tianyi Gao Shukui Wang | 2013 | Molecular Biology Reports2013，，2： | 1 |
| 10 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 11 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 12 | Energy management strategy for fuel cell/battery/ultracapacitor hybrid vehicle based on fuzzy logic显示文摘 | Qi Li Weirong Chen Yankun Li Shukui Liu Jin Huang | 2012 | International Journal of Electrical Power and Energy Systems2012，，1： | 1 |
| 13 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 14 | A Novel magnesium com- posed PLGA/TCP porous scaffold fabricated by 3D printing for bone regeneration 显示文摘 | LAI Yuxiao LI Long CHEN Shukui | 2014 | Journal of Orthopaedic Translation2014，2，4： | 1 |
| 15 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 16 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 17 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 18 | Proteomic-based Analysis for Identification of Proteins Involved in 5-fluorouracil Resistance in Hepatocellular Carcinoma显示文摘 | Yi Tan Shukui Qin Xin Hou Xiujuan Qian Jun Xia Yumei Li Rui Wang Changjie Chen Qingling Yang Lucio Miele Qiong Wu Zhiwei Wang | 2014 | Current Pharmaceutical Design2014，，1： | 1 |
| 19 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 20 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员